Please login to the form below

Not currently logged in
Email:
Password:

Mesoblast

This page shows the latest Mesoblast news and features for those working in and with pharma, biotech and healthcare.

Stem cell therapy promising for rheumatoid arthritis

Stem cell therapy promising for rheumatoid arthritis

Stem cell therapy promising for rheumatoid arthritis. Mesoblast’ s phase II trial sees "impressive efficacy" in refractory patients. ... Mesoblast's MPCs are off-the-shelf, allogeneic stem cell therapies that do not rely on harvesting cells from

Latest news

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    trial; Mesoblast/Teva with allogenic mesenchymal stem cell therapy Neofuse; and Celyad's C-Cure, based on autologous cardiac stem cells.

  • Pharma deals in April 2015 Pharma deals in April 2015

    As mentioned above, Celgene had an exceptionally busy month announcing deals with Quanticel Pharmaceuticals, AZ, Agios Pharmaceuticals, Mesoblast and Northern Biologics. ... Celgene's other deals are with Agios Pharmaceuticals, Mesoblast and AZ. With

  • Medius Deal Watch table for April 2015 Medius Deal Watch table for April 2015

    49. Mesoblast / Celgene. Minority investment and option to license. stem-cell product candidates for conditions including inflammatory bowel disease and certain oncological indications.

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    Commercialisation. Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast .

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Weekly industry appointments Weekly industry appointments

    Weekly industry appointments. GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... Joseph Swedish joins Mesoblast’s board. Cell-based medicines group

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics